WO2005085861A3 - Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer - Google Patents

Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

Info

Publication number
WO2005085861A3
WO2005085861A3 PCT/EP2005/050897 EP2005050897W WO2005085861A3 WO 2005085861 A3 WO2005085861 A3 WO 2005085861A3 EP 2005050897 W EP2005050897 W EP 2005050897W WO 2005085861 A3 WO2005085861 A3 WO 2005085861A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
liver
disorders
cancer
encoded
polypeptides
Prior art date
Application number
PCT/EP2005/050897
Other languages
French (fr)
Other versions
WO2005085861A2 (en )
Inventor
Christian Guelly
Heimo Strohmaier
Charles Buck
Kurt Zatloukal
Original Assignee
Oridis Biomed Forschungs Und E
Christian Guelly
Heimo Strohmaier
Charles Buck
Kurt Zatloukal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

The invention relates to nucleic acids and to corresponding encoded polypeptides and to their use for the diagnosis, prevention and/or treatment of liver disorders and neoplastic disorders, especially cancer of the liver and other epithelial tissues, benign liver neoplasms such as adenoma and other proliferative liver disorders such as focal nodular hyperplasia (FNH) and cirrhosis. The invention further relates to methods of diagnosing and treating these disorders.
PCT/EP2005/050897 2004-03-03 2005-03-01 Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer WO2005085861A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04100858 2004-03-03
EP04100858.2 2004-03-03
EP04100857 2004-03-03
EP04100857.4 2004-03-03

Publications (2)

Publication Number Publication Date
WO2005085861A2 true WO2005085861A2 (en) 2005-09-15
WO2005085861A3 true true WO2005085861A3 (en) 2006-02-02

Family

ID=34921312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/050897 WO2005085861A3 (en) 2004-03-03 2005-03-01 Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

Country Status (1)

Country Link
WO (1) WO2005085861A3 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8986966B2 (en) 2002-09-27 2015-03-24 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US9174222B2 (en) 2005-04-05 2015-11-03 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913697B2 (en) 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
US7842291B1 (en) * 2006-05-22 2010-11-30 Celera Corporation Methods and compositions for diagnosing and treating diseases
EP2201562B1 (en) 2007-09-11 2018-04-25 University of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer
WO2011162558A3 (en) * 2010-06-24 2012-06-28 (주)지노믹트리 Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus
EP2665835B1 (en) 2011-01-18 2018-03-14 Everist Genomics, Inc. Prognostic signature for colorectal cancer recurrence

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281898A (en) * 2000-06-27 2001-01-31 国家人类基因组南方研究中心 Human zinc finger protein isomer and its code sequence
WO2001059063A2 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002029103A2 (en) * 2000-10-02 2002-04-11 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020155513A1 (en) * 1999-04-13 2002-10-24 Hsu Daniel K. Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
WO2002086076A2 (en) * 2001-04-19 2002-10-31 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
WO2003100429A2 (en) * 2002-05-23 2003-12-04 Sunnybrook And Women's College Health Sciences Centre Diagnosis of hepatocellular carcinoma

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155513A1 (en) * 1999-04-13 2002-10-24 Hsu Daniel K. Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
WO2001059063A2 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CN1281898A (en) * 2000-06-27 2001-01-31 国家人类基因组南方研究中心 Human zinc finger protein isomer and its code sequence
WO2002029103A2 (en) * 2000-10-02 2002-04-11 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002086076A2 (en) * 2001-04-19 2002-10-31 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
WO2003100429A2 (en) * 2002-05-23 2003-12-04 Sunnybrook And Women's College Health Sciences Centre Diagnosis of hepatocellular carcinoma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 11 April 2002 (2002-04-11), XP002333985, retrieved from EMBL Database accession no. ACA54656, 05-JUN-2003 *
DATABASE EMBL [online] 20 January 2003 (2003-01-20), XP002333983, retrieved from EMBL Database accession no. ABZ11419, 20-JAN-2003 *
DATABASE EMBL [online] 23 January 2002 (2002-01-23), XP002333984, retrieved from EMBL Database accession no. ABA11768, 23-JAN-2002 *
MIYASAKA Y ET AL: "ANALYSIS OF DIFFERENTIALLY EXPRESSED GENES IN HUMAN HEPATOCELLULAR CARCINOMA USING SUPPRESSION SUBTRACTIVE HYBRIDIZATION", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 85, no. 2, July 2001 (2001-07-01), pages 228 - 234, XP008013867, ISSN: 0007-0920 *
XIAO Q ET AL: "DUTP PYROPHOSPHATASE AND URACIL-DNA GLYCOSYLASE IN RAT LIVER AND HEPATOMAS", INTERNATIONAL JOURNAL OF BIOCHEMISTRY, TARRYTOWN, NY, US, vol. 24, no. 3, 1992, pages 437 - 445, XP002291123 *
XU X-R ET AL: "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 26, 18 December 2001 (2001-12-18), pages 15089 - 15094, XP002231180, ISSN: 0027-8424 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986966B2 (en) 2002-09-27 2015-03-24 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US9174222B2 (en) 2005-04-05 2015-11-03 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US9347100B2 (en) 2006-06-14 2016-05-24 Gpb Scientific, Llc Rare cell analysis using sample splitting and DNA tags
US9273355B2 (en) 2006-06-14 2016-03-01 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9017942B2 (en) 2006-06-14 2015-04-28 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8682594B2 (en) 2008-09-20 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8296076B2 (en) 2008-09-20 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuoploidy by sequencing
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9353414B2 (en) 2008-09-20 2016-05-31 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9404157B2 (en) 2008-09-20 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing

Also Published As

Publication number Publication date Type
WO2005085861A2 (en) 2005-09-15 application

Similar Documents

Publication Publication Date Title
WO2007079164A3 (en) Protein kinase inhibitors
WO2004074455A3 (en) Fc REGION VARIANTS
WO2005031001A3 (en) Novel therapeutic targets in cancer
WO2008036410A3 (en) Methods and compositions for treating amyotrophic lateral sclerosis (als)
WO2007041697A3 (en) Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2005115440A3 (en) Compositions and method for modulating insulin-activated nitric oxide synthase
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007092622A3 (en) Compositions and methods for treating bone
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004072117A3 (en) Antibodies to c-met for the treatment of cancers
WO2003094617A3 (en) Use of vegf for treating bone defects
WO2005085861A3 (en) Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
WO2006050498A3 (en) Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2007035771A3 (en) Modulation of glucagon receptor expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase